Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response accurately distinguishes claims supported by the supplied Reglan tablet labeling from claims absent from that labeling. It correctly identifies support for Reglan as a metoclopramide product and for oral tablet availability, while appropriately noting that orally disintegrating and injectable formulations are not established by the provided sections.
Category Scores
Accurate Statements
Reglan is a brand name for metoclopramide.
Section 11 identifies metoclopramide hydrochloride as the active ingredient of Reglan and states that Reglan tablets contain metoclopramide.
The provided sections do not discuss multiple brand names, countries, or formulations beyond Reglan tablets.
The supplied Sections 3 and 11 describe Reglan tablets but do not mention other brand names, countries, or additional formulations.
Metozolv ODT is not mentioned in the cited Reglan tablet labeling.
The supplied Sections 3 and 11 do not mention Metozolv ODT or orally disintegrating tablets.
Market recognition, leadership, and geographic market status are not established by the FDA label.
The supplied labeling does not address market recognition, market leadership, or United States market status.
The cited Reglan labeling supports oral tablets under Dosage Forms and Strengths and Description.
Section 3 lists 5 mg and 10 mg tablets, and Section 11 states that Reglan tablets are for oral administration.
The provided sections do not establish orally disintegrating tablets or injection formulations.
Sections 3 and 11 describe only Reglan oral tablets and do not identify orally disintegrating or injectable formulations.
The response contains no safety-critical errors or dangerous omissions.
The evaluated claims concern product names and dosage forms; the response does not provide unsafe dosing, administration, or safety instructions.
Unsupported Statements
Those formulations may be addressed in separate FDA-approved metoclopramide product labels.
The supplied prescribing-information sections do not mention separate FDA-approved product labels or establish that orally disintegrating and injectable formulations are addressed elsewhere.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response appropriately limits support to the supplied Reglan tablet labeling and does not provide dosing or treatment instructions. The unsupported reference to possible separate labels is not used to recommend treatment or administration.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One statement extends beyond the supplied labeling by suggesting that other formulations may appear in separate FDA-approved product labels.
Suggested Improvement
Remove the reference to separate labels or state only that the supplied sections do not establish the availability of orally disintegrating or injectable formulations.